Formulation, Development and In-Vitro Evaluation of Immediate Release Tablet of Glibenclamide

Main Article Content

Pravin B. Awate, Dipak P. Kardile, Vishwas C. Bhagat, Ganesh D. More, Tushar B. Shinde, Adinath C. Bhusari, Rajkumar V. Shete, Rani M. Mhetre, Snehal D. Kadbhane, Snehal B. Bagdane


Introduction: Diabetes is treated with Gliblenclamide, an oral antidiabetic medication that encourages the pancreatic beta cells to release insulin.  Glibenclamide belongs to the class of sulphonyl urea class; an oral antidiabetic drug. It causes the pancreatic beta cells to release more insulin, thereby which maintains the blood sugar level. By lowering the hepatic clearance of the hormone, Glibenclamide raises the level of insulin in the blood.

Objectives: According to the biopharmaceutical classification system, Glibenclamide is a member of class II (drugs with poor solubility and high permeability). The major goal of the current investigation was to use the wet granulation method to develop pharmaceutically active, stable, and bioequivalent immediate release (IR) tablets of Glibenclamide.

Methods: Wet granulation method

Results: Utilizing several physical parameters, tools, a dissolution study, and a drug release profile, the formulated formulations were assessed. In order to prepare Gliblenclamide IR tablets, superdisintegrants such as Crosscarmalose sodium and maize starch were mostly used. These substances offer immediate disintegration after ingestion. For the purpose of assessing drug release, in-vitro dissolution testing study was carried out for 1 hours using 0.1N HCl in a dissolution apparatus. Batch F4 performs better and was found to be 100% released in just 30 minutes, according to the dissolution profile.

Article Details